The Women’s Tennis Association has announced a sweeping new eligibility requirement that will fundamentally alter player registration on the WTA Tour. All players competing on the tour must now undergo a one-time genetic sex test to establish eligibility before taking the court.
The testing procedure involves a simple cheek swab, blood sample, or saliva collection designed to detect the presence or absence of the SRY gene. The WTA has confirmed that this new policy takes effect on Tuesday, making it immediately enforceable for all competitors seeking tour participation.
Policy Implementation
The organisation has framed the initiative as a measure to protect competitive integrity across women’s professional tennis. The WTA maintains that the testing protocol will be administered respectfully and with dignity, emphasizing a commitment to fair competition while handling the sensitive nature of genetic testing.
The mandatory nature of the requirement means no player will be exempted from the genetic screening process. Rather than applying selectively to certain competitors or situations, the policy represents a blanket approach affecting the entire tour roster.
Moving Forward on Tour
This marks a significant shift in how the WTA establishes player eligibility. Previously, the tour did not employ genetic testing as a standard requirement for all athletes. The introduction of this screening represents one of professional tennis’s most substantial policy changes in recent years, directly impacting the pathway for every woman seeking to compete at the highest levels of the sport.
The implementation timeline leaves little room for adjustment, with enforcement beginning immediately this week.